1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Osteogenesis imperfecta (OI). OI types I-V. [1] [2] [3] OI types VI-XII. 4 1.2 OMIM# of the disease #166200 (type I), #166210 (type II), #259420 (type III), #166220 (type IV), %610967 (type V), #613982 (type VI), #610682 (type VII), #610915 (type VIII), #259440 (type IX), #613848 (type X), #610968 (type XI), #613849 (type XII). 4, 5 are typically homozygous or compound heterozygous loss-of-function mutations that result in a null allele with severely decreased or no production of normal protein.
Name of the analysed genes or DNA/chromosome segments

Analytical methods
The first step is to perform sequence analysis of the COL1A1 and COL1A2 genes on genomic DNA (gDNA 1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence) OI has a birth prevalence of approximately 6-7/100.000. The prevalence and incidence of the OI types I-V differ from each other with OI type I and OI type IV accounting for more than half of all OI cases. 12 1.9 If applicable, prevalence in the ethnic group of investigated person As the dominantly inherited severe OI types (not OI type I) arise most often from de novo mutations in the COL1A1 and COL1A2 genes, a higher prevalence in particular ethnic groups is not expected. With regard to OI type I: most of the characterized cases are in persons of white European descent and, as such, it is not really possible to comment on whether or not differences in ethnic frequencies exist. One could argue that recessive OI would occur more frequently in inbred populations but this has not been properly studied. However, it is reported that a founder mutation in LEPRE1 is carried by 1.5% of West Africans and 0.4% of African Americans. 13 
Diagnostic setting
Yes No
Comment: DNA analysis in OI is used mainly to confirm the clinical diagnosis. OI types II-V are more easy to diagnose clinically as they usually concern multiple (prenatal) fractures with deformation of bone and specific extraskeletal features (blue sclerae, short length, dentinogenesis imperfecta, hearing loss, early osteoporosis and joint laxity). OI type I can be more difficult to diagnose clinically because the spectrum can extend to nearly asymptomatic individuals with a mild predisposition to fractures, normal stature and normal lifespan 14 as is observed in individuals with idiopathic juvenile osteoporosis. OI type I or sometimes IV are important differential diagnostic considerations in case of suspicion of non-accidental injury (NAI). Predictive testing without clinical symptoms of OI is less common but does occur in specific circumstances. Genetic testing is necessary for genetic risk assessment in relatives. Pre-natal and pre-implantation genetic diagnosis is available for families with a known genetic cause of OI. Specificity:
TEST CHARACTERISTICS
Negative predictive value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Genomic sequencing, if necessary combined with quantitative analysis (MLPA/qPCR/array-based analysis) and in some cases cDNA/mRNA or protein analysis approaches 100% for mutation detection.
Analytical specificity (proportion of negative tests if the genotype is not present)
Analytical specificity is nearly 100%. False positives in genomic sequencing are rare.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Genomic DNA sequencing of the known genes should identify causative variants in more than 95% of individuals with clinically confirmed OI in most populations. 8 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Clinical specificity is nearly 100%.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
For OI inherited both as an autosomal dominant or as an autosomal recessive trait, non-penetrance is rare and positive predictive value approaches 100%. However, the clinical severity of the disease can be difficult to predict due to intra-and interfamilial variability.
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. 3.1.2 Describe the burden of alternative diagnostic methods to the patient Prenatally, the severe OI types (not OI type I) can be diagnosed by ultrasound as fractures occur in the prenatal period. Postnatally, the diagnosis OI can be made, based on patient and family history and by clinical and radiological examination (skeletal overview). 12, 15 The burden of clinical and radiological investigations is very low as is the case with imaging by ultrasound in the prenatal period.
The laboratory diagnosis of OI can also be made in most cases by protein analysis: assessing the production (low or abnormal) of collagen type I by cultured skin fibroblasts (skin biopsy). However, not all patients with OI show abnormalities of collagen type I. Furthermore, the underlying genetic cause is not detected, which makes this technique less suitable for prenatal and unsuitable for preimplantation genetic diagnosis. Lastly, blood sampling for genomic sequencing is a less invasive procedure than a skin biopsy. 8 3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged? With regard to the diagnosis of OI, prenatal ultrasound (OI types II-IV) and postnatal clinical and radiological examination (all types) are relatively cheap and effective. Protein analysis can be useful as a first-line investigation for countries where reimbursement of molecular analysis is not warranted or as a second line of investigation in cases where molecular analysis did not detect any disease-causing variant within COL1A1 or COL1A2 or any of the so-far identified recessive genes. Yes, to a certain extent. In the case of dominant OI, the parents of an index patient will always have to be tested, as will subsequent pregnancies. When it concerns a de novo dominant mutation (parents were both tested and did not harbour the mutation) in an index patient with OI type I, other family members do not need to be tested. When it concerns a severe OI phenotype (not OI type I) in the index patient, and the parents were both tested and did not harbour the mutation, a recurrence risk in a future pregnancy exists (o6%) due to the possibility of germline mosaicism. As such, prenatal diagnosis is possible. Other family members do not need to be tested. However, in the case of an index patient with recessive OI, genetic testing in unaffected relatives is indicated to determine carrier status of recessive OI. 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe). Genetic testing has an additive value in confirming the clinical diagnosis of OI in case of suspicion of NAI but is not always necessary, as the diagnosis can be made based on clinical/radiological examinations whereas a positive genetic test result does not exclude NAI. Genetic testing allows prognostic evaluations to some extent and is the prerequisite for prenatal testing, preimplantation genetic diagnosis and genetic risk calculation in relatives.
